Cepheid (CPHD) Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia
Tweet Send to a Friend
Cepheid (Nasdaq: CPHD) announced the release of its improved Xpert(R) BCR-ABL Monitor test to be marketed as a CE IVD ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
